<div><span style="font-size:24px;">Who We Are:</span></div><div><br></div><div><span style="font-size:11pt;">Technology has transformed the way we work, communicate, travel, eat, move, and more. Yet in biopharma, it still takes 12 years to develop a single drug. Even today, thousands of diseases affecting hundreds of millions of people have no effective treatment. Accelerating the pace of bringing effective, new medicines to patients is one of the greatest opportunities for humanity. </span></div><div><br></div><div><span style="font-size:11pt;">Our mission is to develop better drugs, faster using technology. We have built an end-to-end technology-driven drug discovery platform centered around one of the field’s largest human genomics databases in neuroscience. We use machine learning to map the complex causes of disease and turn those insights into promising drug candidates on our internal biology and chemistry platforms. We are developing drugs to treat some of the biggest medical challenges today: ALS, Parkinson’s Disease, and Alzheimer’s Disease.</span></div><div><br></div><div><span style="font-size:11pt;">We have raised $134M from top tier investors (e.g. BlackRock, Eli Lilly, Merck, Section 32, Threshold Ventures, Y Combinator, etc.). We are a team of engineers, neuroscientists, and drug developers united around an audacious vision: to build the next Genentech of the digital age. </span></div><div><br></div><div><br></div><div><span style="font-size:11pt;">Let’s transform patient lives, together.</span></div><div><br></div>